Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Role of Endoscopy in the Diagnosis, Grading, and Treatment of Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia

S1888 Clinical Relevance and Implications of Gastric Antral Vascular Ectasia (GAVE) in Cirrhotic Patients

The classification of gastric antral vascular ectasia in cirrhotic patients by Versatile Intelligent Staining Technology

Gastric Antral Vascular Ectasia (GAVE) a case report, review of the literature and update of techniques

Gastric Antral Vascular Ectasia: the Evolution of Therapeutic Modalities

Endoscopic treatment for gastric antral vascular ectasia

[Gastric antral vascular ectasia:clinical presentation and therapeutic management]

Endoscopic Ultrasound-Guided Diagnosis and Treatment of Gastric Varices

Influences of etiology and endoscopic appearance on the long-term outcomes of gastric antral vascular ectasia

Gastric Antral Vascular Ectasia: Resolution of Bleeding and Stabilization of Hematocrit Following Orthotopic Liver Transplantation

Role of the posterior mucosal defense barrier in portal hypertensive gastropathy

Endoscopic ultrasound in portal hypertension: navigating venous hemodynamics and treatment efficacy

The misclassification of gastric antral vascular ectasia

AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review

A comparative study of multi-detector CT portography versus endoscopy in evaluation of gastro-esophageal varices in portal hypertension patients

Endoscopic Features and Classification of Gastric Varices in Patients with Portal Hypertension

Comparing Endoscopic Treatment Modalities for Gastric Antral Vascular Ectasia: Efficacy, Safety, and Outcomes in a Network Meta-analysis

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Endoscopic treatment of portal hypertension: current status and future prospects

The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State‐of‐the‐Art Literature Review and Evolving Perspectives

Management of Gastric and Ectopic Varices